<DOC>
	<DOCNO>NCT00794755</DOCNO>
	<brief_summary>The main objective study assess effectiveness low dose Vitamin K1 ( 200 microgram per day ) improve anticoagulation control unstable patient warfarin . This study also aim look effectiveness context gene know influence warfarin metabolism , variability consumption Vitamin K rich food , patient knowledge warfarin anticoagulation -- factor associated anticoagulation control influence effectiveness intervention clinical practice .</brief_summary>
	<brief_title>Low Dose Supplementation Improve Anticoagulation Control With Oral Vitamin K Adjuvant Warfarin Therapy</brief_title>
	<detailed_description>A double-blinded placebo control pilot RCT assess effectiveness daily supplementation low dose Vitamin K1 ( 200 microgram per day ) placebo improve anticoagulation control . Previous study assess efficacy intervention small trial require evaluate true effectiveness safety profile . Furthermore impact genetic polymorphism , know impact warfarin metabolism , effectiveness/safety intervention also assess study . Demographic clinical variable well potential confounding variable variable dietary Vitamin K intake , concomitant interacting medication , anticoagulation knowledge assess study . Given pilot study look recruitment number necessary parameter estimate determine number patient available institution study . Power analysis perform evaluate treatment effect size placebo intervention group .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 1</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>&gt; = 18 year old Have warfarin anticoagulation least 9 month Have INR target range 2.03.0 Have `` unstable '' anticoagulation control , define precede 6 month least 3 INRs range ( &gt; = 3.2 = &lt; 1.8 ) least 3 warfarin dose change Have anticoagulation manage Ottawa Hospital Thrombosis Clinic Able provide write , informed consent Anticipated interruption termination warfarin anticoagulation next six month period 1 week great Patient instability precede six month suspect due ) Interruption warfarin therapy period 1 week b ) Significant noncompliance ( assessed patient record ) Possess know allergy Vitamin K lactose base placebo Unable/Refusal provide write , inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Vitamin K</keyword>
	<keyword>Vitamin K1 ( Phytonadione )</keyword>
	<keyword>Unstable INR</keyword>
	<keyword>VTE Thrombosis</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Anticoagulation Control</keyword>
	<keyword>Patients warfarin unstable anticoagulation control</keyword>
</DOC>